FDA Memo Discussed Pulling Vioxx Based On HMO Study
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA internal memo discusses pulling Merck's Vioxx (rofecoxib) based on the results of a retrospective study sponsored by the agency and Kaiser Permanente
You may also be interested in...
Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes
Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”
Sen. Grassley Seeks FDA Documents On Vioxx Labeling Changes
Senate Finance Committee chair questions why FDA did not adopt recommendations by a cardio-renal division medical officer that a cardiovascular warning be added to Vioxx labeling. Grassley calls FDA’s drug safety initiative “welcome, albeit late in coming.”
Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.